Target Name: ZNF630
NCBI ID: G57232
Review Report on ZNF630 Target / Biomarker Content of Review Report on ZNF630 Target / Biomarker
ZNF630
Other Name(s): MGC138344 | OTTHUMP00000205040 | ZNF630 variant 4 | Zinc finger protein 630, transcript variant 4 | ZN630_HUMAN | FLJ97927 | dJ54B20.2 | Zinc finger protein 630 (isoform 2) | ZNF630 variant 1 | DJ54B20.2 (novel KRAB box containing C2H2 type zinc finger protein) | Zinc finger protein 630, transcript variant 2 | zinc finger protein 630 | dJ54B20.2 (novel KRAB box containing C2H2 type zinc finger protein) | ZNF630 variant 2 | Zinc finger protein 630 (isoform 3) | FLJ20573 | Zinc finger protein 630 (isoform 1) | OTTHUMP00000202169 | ZNF630 variant 3 | Zinc finger protein 630, transcript variant 1 | Zinc finger protein 630, transcript variant 3 | Zinc finger protein 630 | FLJ98691

ZNF630: A Potential Drug Target and Biomarker for Various Diseases

ZNF630 (MGC138344) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ZNF630 is a non-coding RNA molecule that is expressed in various tissues and cells throughout the body. It is a key regulator of cell proliferation and has been involved in the development and progression of many diseases.

The ZNF630 gene was first identified in the late 1990s using transcriptomic studies. It is located on chromosome 6 and has been shown to be involved in the regulation of various cellular processes, including cell growth, differentiation, and apoptosis (programmed cell death). ZNF630 has also been shown to be involved in the regulation of gene expression and has been identified as a potential drug target in various diseases.

One of the most promising aspects of ZNF630 is its potential as a drug target for cancer. Cancer is a leading cause of death worldwide and is a major driver of disability. Many cancer treatments are effective in the short term but have a negative impact on quality of life and survival in the long term. Therefore, identifying potential drug targets is a promising way to improve cancer treatment outcomes. ZNF630 has been shown to be involved in the regulation of cell proliferation and has been identified as a potential drug target for various cancers, including breast, ovarian, and colorectal cancers.

ZNF630 has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. These conditions are characterized by the progressive loss of brain cells and can have a significant impact on an individual's quality of life and independence. ZNF630 has been shown to be involved in the regulation of neurodegenerative disease-related gene expression and has been identified as a potential drug target for these conditions.

In addition to its potential as a drug target, ZNF630 has also been shown to be involved in the regulation of autoimmune disorders. Autoimmune disorders are a leading cause of disease and can cause significant morbidity and mortality. ZNF630 has been shown to be involved in the regulation of autoimmune disorder-related gene expression and has been identified as a potential drug target for these conditions.

Overall, ZNF630 is a promising gene that has the potential to be a drug target and biomarker for various diseases. Further research is needed to fully understand its functions and potential clinical applications.

Protein Name: Zinc Finger Protein 630

Functions: May be involved in transcriptional regulation

The "ZNF630 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF630 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF638 | ZNF639 | ZNF641 | ZNF644 | ZNF646 | ZNF648 | ZNF649 | ZNF652 | ZNF652-AS1 | ZNF653 | ZNF654 | ZNF655 | ZNF658 | ZNF658B | ZNF66 | ZNF660 | ZNF662 | ZNF663P | ZNF664 | ZNF664-RFLNA | ZNF665 | ZNF667 | ZNF667-AS1 | ZNF668 | ZNF669 | ZNF670 | ZNF670-ZNF695 | ZNF671 | ZNF672 | ZNF674 | ZNF674-AS1 | ZNF675 | ZNF676 | ZNF677 | ZNF678 | ZNF679 | ZNF680 | ZNF681 | ZNF682 | ZNF683 | ZNF684 | ZNF687 | ZNF688 | ZNF689 | ZNF69 | ZNF691 | ZNF692 | ZNF695 | ZNF696 | ZNF697 | ZNF699 | ZNF7 | ZNF70 | ZNF700 | ZNF701 | ZNF702P | ZNF703 | ZNF704 | ZNF705A | ZNF705B | ZNF705CP | ZNF705EP | ZNF705G | ZNF706 | ZNF707 | ZNF708 | ZNF709 | ZNF71 | ZNF710 | ZNF711 | ZNF713 | ZNF714 | ZNF716 | ZNF717 | ZNF718 | ZNF721 | ZNF723 | ZNF724 | ZNF726 | ZNF727 | ZNF728 | ZNF729 | ZNF730 | ZNF732 | ZNF734P | ZNF735 | ZNF736 | ZNF737 | ZNF738 | ZNF74 | ZNF740 | ZNF746 | ZNF747 | ZNF749 | ZNF750 | ZNF75A | ZNF75CP | ZNF75D | ZNF76 | ZNF761